<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02040506</url>
  </required_header>
  <id_info>
    <org_study_id>IGN523-01</org_study_id>
    <nct_id>NCT02040506</nct_id>
  </id_info>
  <brief_title>A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML</brief_title>
  <official_title>A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Igenica Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Igenica Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and tolerability of IGN523 administered as an IV infusion.&#xD;
      The main purpose of the study is to determine the maximum tolerated dose (MTD), which is the&#xD;
      highest dose that does not cause unacceptable side effects of IGN523 in patients with acute&#xD;
      myeloid leukemia (AML). The MTD will be determined by observing the dose-limiting toxicities&#xD;
      (the side effects that prevent further increases in dose) of IGN523. In addition, the&#xD;
      pharmacokinetic profile and anti-leukemia activity of IGN523 will be assessed. A recommended&#xD;
      Phase 2 dose (RP2D) of IGN523 will be identified, on the basis of safety, pharmacokinetic&#xD;
      (PK), and pharmacodynamic (PD) data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  Evaluate the safety and tolerability of IGN523 administered weekly&#xD;
&#xD;
        -  Determine the MTD and dose limiting toxicity (DLT) of IGN523 when administered weekly&#xD;
           during the DLT Evaluation Period&#xD;
&#xD;
        -  Identify a recommended Phase 2 dose (RP2D) of IGN523 on the basis of safety, PK, and PD&#xD;
           data&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Assess the incidence of antibody formation to IGN523&#xD;
&#xD;
        -  Characterize the PK of IGN523 in subjects with relapsed or refractory AML&#xD;
&#xD;
        -  Perform a preliminary assessment of the anti-leukemic activity of IGN523 in subjects&#xD;
           with relapsed or refractory AML&#xD;
&#xD;
        -  Perform a preliminary assessment of biologic markers that might predict IGN523&#xD;
           anti-leukemic activity&#xD;
&#xD;
      Estimated Enrollment: 50 Study Start Date: February 2014 Estimated Study Completion Date:&#xD;
      March 2016 Estimated Primary Completion Date: September 2015 (Final data collection for&#xD;
      primary outcome measure)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of antidrug antibodies to IGN523</measure>
    <time_frame>Through 6 months following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of IGN523</measure>
    <time_frame>Through 6 months following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess anti-leukemic activity of IGN523</measure>
    <time_frame>Initial assessment after 8 weeks of treatment</time_frame>
    <description>Subjects with measurable disease will be assessed by standard criteria (Cheson). Subjects will be formally evaluated for response at the end of Cycle 2; additional evaluations may be performed during the study as clinical indicated.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>IGN523</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGN523</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGN523</intervention_name>
    <description>Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.</description>
    <arm_group_label>IGN523</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Relapsed or treatment-refractory AML&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group status 0-2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate baseline renal and hepatic function&#xD;
&#xD;
          -  Measurable disease (eg, peripheral blasts greater than 5%)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic myelogenous leukemia in blast crisis&#xD;
&#xD;
          -  Monoclonal therapy within 4 weeks, or chemotherapy or radiotherapy within 2 weeks&#xD;
&#xD;
          -  Unresolved acute toxicity from prior anti-cancer therapy&#xD;
&#xD;
          -  Prior allogeneic stem cell transplant and active graft-versus-host disease requiring&#xD;
             systemic immunosuppressive therapy within 15 days prior to screening&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to monoclonal antibody therapy&#xD;
&#xD;
          -  Known current leptomeningeal or central nervous system (CNS) involvement of leukemia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Ho, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Igenica Biotherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center / Thornton Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute, Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplantation Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>January 16, 2014</study_first_submitted>
  <study_first_submitted_qc>January 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2014</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Drug therapy</keyword>
  <keyword>CD98</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>Monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

